A Modified Recombinant DNA-Based SARS-CoV-2 Vaccine Expressing Stabilized Uncleavable Spike Protein Elicits Humoral and Cellular Immunity against Various SARS-CoV-2 Variants of Concern

<div>The median inhibitory concentration (IC<sub>50</sub>) of neutralizing antibodies (nAbs) induced by VIU-1007. The IC<sub>50</sub> values of nAbs were determined against the different rVSV-<i>Δ</i>G-based pseudoviruses, including ancestral Wuhan strain and SARS-CoV-2 VOC alpha, beta, gamma, delta, and omicron as well as SARS-CoV, Bat SARS-like coronavirus WIV1, and MERS-CoV. Data are shown as mean ± SD. Titers are reported as geometric mean titers.</div>

Transboundary and Emerging Diseases

fig4

Figure 4

Figure 4: A Modified Recombinant DNA-Based SARS-CoV-2 Vaccine Expressing Stabilized Uncleavable Spike Protein Elicits Humoral and Cellular Immunity against Various SARS-CoV-2 Variants of Concern 

Figure 4 | A Modified Recombinant DNA-Based SARS-CoV-2 Vaccine Expressing Stabilized Uncleavable Spike Protein Elicits Humoral and Cellular Immunity against Various SARS-CoV-2 Variants of Concern 